Table 1.
APL patients’ characteristics and results of ATO therapy
| No. | Sex/age | Diagnosis | Blasts (BM%) | WBC (×109/l) | Plts (×109/l) | Hb (g/l) | Outcome |
|---|---|---|---|---|---|---|---|
| 1 | F/44 | M3/bcr1 | 80 | 5.1 | 43 | 62 | HCR |
| 2 | F/45 | M3/bcr1 | 84 | 10.4 | 27 | 57 | HCR |
| 3 | M/34 | M3/bcr3 | 78 | 4.5 | 37 | 77 | HCR |
| 4 | M/38 | M3/bcr1 | 88 | 11.2 | 33 | 68 | HCR |
| 5 | F/17 | M3/bcr3 | 88 | 28.2 | 26 | 90 | HCR |
| 6 | F/44 | M3/bcr1 | 85 | 18.2 | 45 | 67 | HCR |
| 7 | F/42 | M3/bcr1 | 95 | 25.7 | 31 | 77 | PR |
| 8 | M/41 | M3/bcr1 | 92 | 26.1 | 22 | 60 | PR |
| 9 | M/45 | M3/bcr1 | 87 | 14.2 | 14 | 77 | HCR |
| 10 | F/34 | M3/bcr1 | 90 | 32.5 | 12 | 79 | HCR |
| 11 | M/53 | M3/bcr3 | 92 | 20.4 | 77 | 58 | PR |
| 12 | F/29 | M3/bcr1 | 91 | 24.4 | 34 | 86 | HCR |
| 13 | M/39 | M3/bcr3 | 94 | 6.2 | 37 | 66 | HCR |
| 14 | M/35 | M3/bcr3 | 94 | 26.2 | 33 | 76 | HCR |
| 15 | M/62 | M3/bcr1 | 80 | 4.5 | 55 | 76 | HCR |
| 16 | M/23 | M3/bcr1 | 89 | 4.1 | 12 | 62 | HCR |
| 17 | M/33 | M3/bcr1 | 82 | 20.2 | 13 | 61 | ED |
| 18 | M/23 | M3/bcr3 | 81 | 18.9 | 19 | 62 | HCR |
| 19 | F/39 | M3/bcr3 | 83 | 17.7 | 12 | 68 | HCR |
| 20 | F/41 | M3/bcr1 | 87 | 12.8 | 32 | 55 | PR |
| Ref. range | 0–0.4 | 4–10 | 100–300 | 110–170 | HCR | ||
The main clinical and laboratory features of 20 newly diagnosed APL patients and results of ATO therapy during induction therapy
Blasts promyelocytes + blasts, PB peripheral blood, WBC white blood cell, Plts platelets, Hb hemoglobin, bcr breakpoint cluster region (bcr1 = intron 6, bcr3 = intron 3), HCR complete hematologic remission, PR partial remission, ED early death